VRG Miniproteins

Designed for developability. Engineered with precision.

Our proprietary platform, AI-MPRO, unites computational protein design with wet-lab–based directed evolution, creating therapeutic miniproteins with high potency, selectivity, and developability built in from the start.
Down Arrow icon purple
Our Mission

VRG Therapeutics is pioneering a new era of AI-driven drug discovery, combining state-of-the-art in silico and wet-lab capabilities to create miniproteins with extreme selectivity and outstanding affinity.

Our mission is to cure diseases via targets and mechanisms of action that cannot be reached with traditional approaches.

Using our proprietary platform, AI-MPRO, we design and optimize miniproteins with precision through de novo computational design and directed evolution. This approach lets us pursue a diverse portfolio of targets with a single, unified platform — giving us both the flexibility to tackle hard-to-reach biology and the long-term stability to build a durable pipeline.
Image of a miniprotein
Benefits

Why do we work with miniproteins?

Miniproteins combine the benefits of small molecules and large biologics, and — unlike antibodies or small molecules constrained by fixed scaffolds or chemical space — can be designed from scratch to match the exact requirements of a given target or mechanism of action. This makes them an ideal next-generation therapeutic modality for targets intractable by antibodies and small molecules.
Our Platform

ai-powered miniprotein platform

Our miniprotein-based drug discovery platform, AI-MPRO, provides an integrated path from target selection through in vivo proof of concept, rapidly advancing differentiated therapeutic candidates with high potency, precision, a compelling safety profile, and best-in-class potential.
See Our Platform
White right arrow icon
A horizontal bar chart titled 'Our Projects Pipeline' showing progress of five projects: Kv1.3 with the longest dark blue bar, IL-6 with a medium-length lavender bar, CNS/IL-6 with a shorter blue bar, and two faint bars for CNS/NT #1 and CNS/NT #2 with minimal progress indicated.
Pipeline

Our Pipeline

Our projects are managed applying state-of-the-art project management approach for drug discovery and development.
Project Initiation
Clinical Development
See Our Pipeline
White right arrow icon
Careers

Join our team

We are constantly looking for world-class talent, join us if you want to work in an agile environment to stay ahead of the game in healthcare.
Check mark in a dark square icon
cutting-edge technologies
Check mark in a dark square icon
diverse portfolio
Check mark in a dark square icon
Seasoned team with global experience
See Vacancies
White right arrow icon
Researcher placing a sample slide under a microscope
Resources
Latest News
See All News
White right arrow icon
Resources

Latest News

See All News
White right arrow icon
Resources
Latest News
See All News
White right arrow icon
Kv1.3
May 12, 2026
By VRG Therapeutics
Press Release
Kv1.3
April 13, 2026
By VRG Therapeutics
VRG Miniprotein Secures €4M Catalyst Grant to Advance Kv1.3 Program
CREATe-1
April 2, 2026
By VRG Therapeutics
CREATe Therapeutics
Conference
January 28, 2026
By VRG Therapeutics
2026 International Roadshow Begins
Team
January 18, 2026
By VRG Therapeutics
New Joiner R&D Director of Drug Discovery
Analytics
January 18, 2026
By VRG Therapeutics
New International Collaboration: VRG Therapeutics Awarded Grant for Biased Drug Discovery Research
VRG-145
January 18, 2026
By VRG Therapeutics
Novamigra Therapeutics Secures- Funding-First-in-Human Study of Migraine Prophylaxis Asset VRG-145
Conference
December 4, 2025
By VRG Therapeutics
VRG Presenting at Re:Biotech Hungary
Conference
December 1, 2025
By VRG Therapeutics
CREATe Therapeutics Showcases Drug-Controlled Gene Therapy Platform at CGTI EU
Team
September 14, 2025
By VRG Therapeutics
New Joiner Márton A. Simon PhD in our Team
Kv1.3
May 12, 2026
By VRG Therapeutics
Press Release
Kv1.3
April 13, 2026
By VRG Therapeutics
VRG Miniprotein Secures €4M Catalyst Grant to Advance Kv1.3 Program
CREATe-1
April 2, 2026
By VRG Therapeutics
CREATe Therapeutics
Conference
January 28, 2026
By VRG Therapeutics
2026 International Roadshow Begins
Team
January 18, 2026
By VRG Therapeutics
New Joiner R&D Director of Drug Discovery
Analytics
January 18, 2026
By VRG Therapeutics
New International Collaboration: VRG Therapeutics Awarded Grant for Biased Drug Discovery Research
VRG-145
January 18, 2026
By VRG Therapeutics
Novamigra Therapeutics Secures- Funding-First-in-Human Study of Migraine Prophylaxis Asset VRG-145
Conference
December 4, 2025
By VRG Therapeutics
VRG Presenting at Re:Biotech Hungary
Conference
December 1, 2025
By VRG Therapeutics
CREATe Therapeutics Showcases Drug-Controlled Gene Therapy Platform at CGTI EU
Team
September 14, 2025
By VRG Therapeutics
New Joiner Márton A. Simon PhD in our Team
Kv1.3
May 12, 2026
By VRG Therapeutics
Press Release
Kv1.3
April 13, 2026
By VRG Therapeutics
VRG Miniprotein Secures €4M Catalyst Grant to Advance Kv1.3 Program
CREATe-1
April 2, 2026
By VRG Therapeutics
CREATe Therapeutics
Conference
January 28, 2026
By VRG Therapeutics
2026 International Roadshow Begins
Team
January 18, 2026
By VRG Therapeutics
New Joiner R&D Director of Drug Discovery
Analytics
January 18, 2026
By VRG Therapeutics
New International Collaboration: VRG Therapeutics Awarded Grant for Biased Drug Discovery Research
VRG-145
January 18, 2026
By VRG Therapeutics
Novamigra Therapeutics Secures- Funding-First-in-Human Study of Migraine Prophylaxis Asset VRG-145
Conference
December 4, 2025
By VRG Therapeutics
VRG Presenting at Re:Biotech Hungary
Conference
December 1, 2025
By VRG Therapeutics
CREATe Therapeutics Showcases Drug-Controlled Gene Therapy Platform at CGTI EU
Team
September 14, 2025
By VRG Therapeutics
New Joiner Márton A. Simon PhD in our Team
Slider move or slide items to left purple arrow icon
Slider move or slide items to right purple arrow icon
Slider move or slide items to left purple arrow icon
Slider move or slide items to right purple arrow icon